Suven Life Sciences
- Market cap
- ₹ 7,420 Cr.
- P/E
- 2.6x
- P/B
- 11.96x
- 52-week range
- 124.11 – 403.35
- ROE
- −82%
- ROCE
- −80%
- Dividend yield
- 0%
- Debt / equity
- 0.03
- Sector
- Healthcare Services
- Industry
- Healthcare Research, Analytics & Technology
- Listed on
- NSE, BSE
About
Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Research, Analytics & Technology: 11 companies →Suven Life Sciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)2.6 against a typical 33.1: cheaper than most peers (1st = cheapest).1st of 11
- Sales growth+100% against a typical +16.4% from a year earlier.2nd of 10
- Share price, 3 months−15.1% against a typical −11.4%.8th of 11
- Size₹ 7,420.1 Cr. market value against a typical ₹ 197.8 Cr. (1st = largest).3rd of 11
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 6 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 29 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 11 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 13 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 13 May 2025 | Financial Results/Fund Raising | To consider and approve the financial results for the period ended March 31, 2025 and Fund Raising |
| 24 Jan 2025 | Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| Expenses | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 |
| Operating Profit | −24 | −46 | −30 | −31 | −52 | −39 | −44 | −51 | −80 | −103 | −51 | −132 |
| OPM % | −768% | −1,885% | −1,267% | −3,024% | −2,032% | −2,435% | −2,981% | −2,714% | −8,671% | −3,678% | −3,331% | −3,711% |
| Other Income | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | −13 | −42 | −28 | −28 | −50 | −39 | −44 | −52 | −77 | −102 | −46 | −128 |
| Tax % | 0% | 0% | −4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −13 | −42 | −27 | −28 | −50 | −39 | −44 | −52 | −77 | −102 | −46 | −128 |
| EPS in Rs | −0.58 | −1.91 | −1.22 | −1.29 | −2.28 | −1.79 | −2.01 | −2.36 | −3.4 | −4.48 | −1.73 | −4.83 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −35%
- 5 Years
- −12%
- 3 Years
- −19%
- TTM
- 17%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −91%
- 10 Years
- 40%
- 5 Years
- 37%
- 3 Years
- 79%
- TTM
- —
- 10 Years
- −24%
- 5 Years
- −68%
- 3 Years
- −66%
- TTM
- —
Peers
Listed companies in the same business.
| Suven Life Sciences | ₹ 266.10 | ₹ 7,420 Cr. | 2.6x | 12x | −82% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Venkateswarlu Jasti
- Executive Chairman of the Board, Managing Director
- M. Mohan Kumar
- Chief Financial Officer
- Sangeetha Laxmi Kandari
- Company Secretary and Compliance Officer
- Sudha Rani Jasti
- Wholetime Director
Prices are delayed and for information only. Nothing on this page is investment advice.